Trk antagonists, particularly TrkA inhibitors of NGF, are being investigated for prostate and breast cancer, pain, and arrhythmogenic right-ventricular dysplasia [15]. This evidence concerns the gene NTRK1 and arrhythmogenic right ventricular cardiomyopathy.